2023 Publication list
2023 Publication list
2023年度（2023年4月―2024年3月）論文
1. Yamasaki F, Fudaba H, Asano K, Sasayama T, Natsumeda M, Shimabukuro T, et al. Multidrug chemotherapy, whole-brain radiation and cytarabine therapy for primary central nervous system lymphoma in elderly patients with dose modification based on geriatric assessment: study protocol for a phase II, multicentre, non-randomised study. BMJ Open 2023;13(4):e071350.
2. Goto Y, Kenmotsu H, Tamiya M, Murakami S, Kurata T, Yanagitani N, et al. A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan. JTO Clin Res Rep 2023;4(5):100508.
3. Sugawara S, Tanaka K, Imamura F, Yamamoto N, Nishio M, Okishio K, et al. Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407. Cancer Sci 2023;114(8):3330-3341.
4. Yamamoto H, Soh J, Okumura N, Suzuki H, Nakata M, Fujiwara T, et al. Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201. PLoS One 2023;18(5):e0285273.
5. Fujiwara T, Shien K, Matsuura M, Soh J, Yamamoto H, Takao S, et al. EGFR Mutation is a Prognostic Factor in Lung Cancer Patients with Pleural Dissemination Detected During or After Surgery. Ann Surg Oncol 2023;30(11):6697-6702.
6. Goto Y, Kawamura K, Fukuhara T, Namba Y, Aoe K, Shukuya T, et al. Health Care Resource Use Among Patients with Advanced Non-Small Cell Lung Cancer in Japan, 2017-2019. Curr Ther Res Clin Exp 2023;99:100712.
7. Kakugawa T, Doi K, Ohteru Y, Kakugawa H, Oishi K, Kakugawa M, et al. Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan. Immun Ageing 2023;20(1):42.
8. Ninomiya T, Ishikawa N, Kozuki T, Kuyama S, Inoue K, Yokoyama T, et al. A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naive patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer 2023;184:107349.
9. Kunihiro Y, Matsumoto T, Murakami T, Shimokawa M, Kamei H, Tanaka N, et al. A quantitative analysis of long-term follow-up computed tomography of idiopathic pulmonary fibrosis: the correlation with the progression and prognosis. Acta Radiol 2023;64(8):2409-2415.
10. Ikeda S, Tsuboi M, Sakai K, Misumi T, Akamatsu H, Shoda H, et al. NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study. Mol Oncol 2024;18(2):305-316.
11. Yamaguchi O, Mori K, Takata S, Shibata K, Chikamori K, Kimura N, et al. Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study). Thorac Cancer 2024;15(2):163-171.
12. Hasegawa S, Shintani Y, Takuwa T, Aoe K, Kato K, Fujimoto N, et al. Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan. Cancer Sci 2024;115(2):507-528.
13. Kawamoto N, Okita R, Okada M, Hayashi M, Inokawa H. Intraoperative chylous leak diagnosis by preoperative oral administration of ice cream: a case report. AME Case Rep 2024;8:8.
14. Katayama H, Tabata M, Kamei H, Mimura Y, Maeda Y. Relationship Between Corticosteroid Administration and Survival Period in Terminal Cancer Patients. J Palliat Care 2024;39(3):238-243.
15. Tanaka A, Okita R, Morishige T, Okada M, Inokawa H, Hirazawa K, et al. A case of primary lung adenocarcinoma mimicking metastatic papillary thyroid carcinoma. Thorac Cancer 2024;15(4):353-357.
16. Morise M, Kato T, Matsumoto S, Inoue T, Sakamoto T, Tokito T, et al. Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study. Cancer Sci 2024;115(4):1296-1305.
17. Karashima T, Mimura-Kimura Y, Mimura Y. Albuterol Delivery via In-Line Intrapulmonary Percussive Ventilation Superimposed on Invasive Ventilation in an Adult Lung Model. Respir Care 2024;69(9):1092-1099.
18. 石光雄大（2024）「勉強会どうしてますか?〈2〉呼吸療法・呼吸リハビリテ
ーションにおける参加型の研修開催」総合リハビリテーション 52巻2号193-195
19．辛島隆司、三村由香、石本望実、中村亮裕、宮川奏、三村雄輔（2023）
「Intrapulmonary percussive ventilator(IPV)のバクテリアフィルタによるエアロゾ
ル暴露対策と安全性の検証」医療の広場63巻9号21－24
20．石光雄大（2023）「効果的な呼吸理学療法に向けた医療機器活用のコツ」
理学療法ジャーナル57巻9号1139-1141
1. Yamasaki F, Fudaba H, Asano K, Sasayama T, Natsumeda M, Shimabukuro T, et al. Multidrug chemotherapy, whole-brain radiation and cytarabine therapy for primary central nervous system lymphoma in elderly patients with dose modification based on geriatric assessment: study protocol for a phase II, multicentre, non-randomised study. BMJ Open 2023;13(4):e071350.
2. Goto Y, Kenmotsu H, Tamiya M, Murakami S, Kurata T, Yanagitani N, et al. A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan. JTO Clin Res Rep 2023;4(5):100508.
3. Sugawara S, Tanaka K, Imamura F, Yamamoto N, Nishio M, Okishio K, et al. Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407. Cancer Sci 2023;114(8):3330-3341.
4. Yamamoto H, Soh J, Okumura N, Suzuki H, Nakata M, Fujiwara T, et al. Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201. PLoS One 2023;18(5):e0285273.
5. Fujiwara T, Shien K, Matsuura M, Soh J, Yamamoto H, Takao S, et al. EGFR Mutation is a Prognostic Factor in Lung Cancer Patients with Pleural Dissemination Detected During or After Surgery. Ann Surg Oncol 2023;30(11):6697-6702.
6. Goto Y, Kawamura K, Fukuhara T, Namba Y, Aoe K, Shukuya T, et al. Health Care Resource Use Among Patients with Advanced Non-Small Cell Lung Cancer in Japan, 2017-2019. Curr Ther Res Clin Exp 2023;99:100712.
7. Kakugawa T, Doi K, Ohteru Y, Kakugawa H, Oishi K, Kakugawa M, et al. Kinetics of COVID-19 mRNA primary and booster vaccine-associated neutralizing activity against SARS-CoV-2 variants of concern in long-term care facility residents: a prospective longitudinal study in Japan. Immun Ageing 2023;20(1):42.
8. Ninomiya T, Ishikawa N, Kozuki T, Kuyama S, Inoue K, Yokoyama T, et al. A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naive patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer 2023;184:107349.
9. Kunihiro Y, Matsumoto T, Murakami T, Shimokawa M, Kamei H, Tanaka N, et al. A quantitative analysis of long-term follow-up computed tomography of idiopathic pulmonary fibrosis: the correlation with the progression and prognosis. Acta Radiol 2023;64(8):2409-2415.
10. Ikeda S, Tsuboi M, Sakai K, Misumi T, Akamatsu H, Shoda H, et al. NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study. Mol Oncol 2024;18(2):305-316.
11. Yamaguchi O, Mori K, Takata S, Shibata K, Chikamori K, Kimura N, et al. Extended ICI treatment after first-line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non-small lung cancer: Post hoc analysis from NEJ051 (REACTIVE study). Thorac Cancer 2024;15(2):163-171.
12. Hasegawa S, Shintani Y, Takuwa T, Aoe K, Kato K, Fujimoto N, et al. Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan. Cancer Sci 2024;115(2):507-528.
13. Kawamoto N, Okita R, Okada M, Hayashi M, Inokawa H. Intraoperative chylous leak diagnosis by preoperative oral administration of ice cream: a case report. AME Case Rep 2024;8:8.
14. Katayama H, Tabata M, Kamei H, Mimura Y, Maeda Y. Relationship Between Corticosteroid Administration and Survival Period in Terminal Cancer Patients. J Palliat Care 2024;39(3):238-243.
15. Tanaka A, Okita R, Morishige T, Okada M, Inokawa H, Hirazawa K, et al. A case of primary lung adenocarcinoma mimicking metastatic papillary thyroid carcinoma. Thorac Cancer 2024;15(4):353-357.
16. Morise M, Kato T, Matsumoto S, Inoue T, Sakamoto T, Tokito T, et al. Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study. Cancer Sci 2024;115(4):1296-1305.
17. Karashima T, Mimura-Kimura Y, Mimura Y. Albuterol Delivery via In-Line Intrapulmonary Percussive Ventilation Superimposed on Invasive Ventilation in an Adult Lung Model. Respir Care 2024;69(9):1092-1099.
18. 石光雄大（2024）「勉強会どうしてますか?〈2〉呼吸療法・呼吸リハビリテ
ーションにおける参加型の研修開催」総合リハビリテーション 52巻2号193-195
19．辛島隆司、三村由香、石本望実、中村亮裕、宮川奏、三村雄輔（2023）
「Intrapulmonary percussive ventilator(IPV)のバクテリアフィルタによるエアロゾ
ル暴露対策と安全性の検証」医療の広場63巻9号21－24
20．石光雄大（2023）「効果的な呼吸理学療法に向けた医療機器活用のコツ」
理学療法ジャーナル57巻9号1139-1141